urnberg HG et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil. JAMA.

2003;289:56.

Segraves RT et al. Tadalafil for treatment of erectile dysfunction in men on antidepressants. J Clin

Psychopharmacol. 2007;27(1):62–66.

Shrivastava RK et al. Amantadine in the treatment of sexual dysfunction associated with selective serotonin

reuptake inhibitors. J Clin Psychopharmacol. 1995;15:83.

Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors.

Depression. 1994;2:109.

Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open-label trial of yohimbine. J Clin Psychiatry.

1992;53:119.

Michelson D et al. Female sexual dysfunction associated with antidepressant administration: a randomized,

placebocontrolled study of pharmacologic intervention. Am J Psychiatry. 2000;157:239.

Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther.

1998;24:139.

Gelenberg AJ et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry.

2000;61(5):356–360.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Delgado PL et al. Treatment strategies for depression and sexual dysfunction. J Clin Psychiatry. 1999;17:15.

Gunnell D et al. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: a meta-analysis of drug

company data from placebo controlled, randomized controlled trials submitted to the MHRA’s safety review.

BMJ. 2005;330:385–390.

Isacsson G, Rich CL. Antidepressant drugs and the risk of suicide in children and adolescents. Pediatr Drugs.

2014;16:115–122.

Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin

Psychiatry. 2001;3:22–27.

Modi S, Lowder D. Medications for migraine prophylaxis. Am Fam Phys. 2006;73(1):72–78.

Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27:1295–1230.

Vida S, Looper K. Precision and comparability of adverse event rates of newer antidepressants. J Clin

Psychopharmacol. 1999;19:416.

Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005;39:748–752.

Mercadante S. Hyoscine in opioid-induced sweating. J Pain Symptom Manage. 1998;15:214.

Romanelli F et al. Possibleparoxetine-inducedbruxism. Ann Pharmacother. 1996;30:1246.

Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry. 1993;54:432.

Rugh JD, Harlan J. Nocturnal bruxism and temporomandibular disorders. Adv Neurol. 1988;49:329.

Kirby D, Ames D. Hyponatremia and selective serotonin reuptake inhibitors in elderly patients. Int J Geriatr

Psychiatry. 2001;16:484.

Arinzon ZH et al. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother. 2002;36:1175.

Leo RJ. Movement disorders associated with selective serotonin reuptake inhibitors. J Clin Psychiatry.

1996;57:449.

Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother.

1997;31:1481–1489.

Lane RM. SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment. J

Psychopharmacol. 1998;12(2):192–214.

Levine LR et al. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obes.

1987;11(Suppl 3):185.

Fava M et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with

long-term treatment. J Clin Psychiatry. 2000;61:863–867.

Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ. 2005;331:529.

Anglin R et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without

concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol.

2014;109:811–819.

Vidal X et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by

antidepressants: a case-controlstudy. Drug Saf. 2008;31:159.

Lewis JD et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper

gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008;17:328.

Depression Guideline Panel. Rockville, MD: Agency for Health Policy and Research, US Dept of Health and

Human Services; 1993.

Felice D et al. When aging meets the blues: are the current antidepressants effective in depressed aged

patients? Neurosci Biobehav Rev. 2015;55:478–497.

Warner CH et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449–457.

Baldessarini RJ et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J

Psychiatry. 2010;167:934.

Davies S et al. Depression, suicide, and the nationalservice framework. BMJ. 2001;322:1500–1501.

Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry. 1997;54:989.

Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry.

2002;63:24.

Cohen LS et al. Relapse of major depression during pregnancy in women who maintain or discontinue

antidepressant treatment [published correction appears in JAMA. 2006;296:170]. JAMA. 2006;295:499.

Chaudron LH. Complex challenges in treating depression during pregnancy. Am J Psychiatry. 2013;170:12–20.

Louik C et al. First-trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. N Engl J

Med. 2007;356:2675.

Alwan S et al. Use of serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med.

.

.

.

.

.

.

.

.

.

.

136.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

151.

.

.

.

2007;356:2684.

Berard A et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the

importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18.

Laine K et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic

symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry.

2003;60:720.

Wisner KL et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? Am J Psychiatry.

2013;170:485–493.

Einarson A et al. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy:

results from a large prospective database. J Obstet Gynaecol Can. 2009;31:452.

O’Connor E et al. Primary care screening for and treatment of depression in pregnant and postpartum women.

Evidence report and systematic review for the US Preventative Services Task Force. JAMA.

2016;315(4):388–406.

Yonkers KA et al. The management of depression during pregnancy: a report from the American Psychiatric

Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31:403.

Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005;28(2):138–152.

Spigstet O, Hagg S. Excretion of psychotropic drugs into breast milk: pharmacokinetic overview and therapeutic

implications. CNS Drugs. 1998;9:111.

Wisner KL et al. Serum sertraline and n-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J

Psychiatry. 1998;155:690.

Greenblatt DJ et al. Human cytochromes and some new antidepressants: kinetics, metabolism and drug

interactions. J Clin Psychopharmacol. 1999;19(5 Suppl 1):23S.

Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with

emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(suppl

1):1–21.

Preskorn SH et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6

function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28–34.

Spina E et al. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67.

Jefferson JW, Griest JH. Brusselsprouts and psychopharmacology: understanding the cytochrome P450 system.

Psychiatr Clin North Am. 1996;3:205.

Igbal MM et al. Overview of serotonin syndrome. Ann Clin Psychiatr. 2012;24(4):310–318.

Graber MA et al. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother.

1994;28:732.

Iruela LM et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150:522.

Lantz MS et al. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol.

1999;12:7.

Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705.

Nierenberg AA et al. Trazodone for antidepressant associated insomnia. Am J Psychiatry. 1994;151:1069.

Wilson SJ et al. British Association for Psychopharmacology consensus statement on evidence-based treatment

of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;1–25.

Rush AJ et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment

steps: a STAR*D report. Am J Psychiatry. 2006;163:1905.

Paykel ES et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med.

1995;25:1171.

Gibson TB et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care.

2010;16:370.

Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant

to another? J Clin Psychiatry. 1995;56:30.

Thase ME et al. Citalopram treatment of paroxetine intolerant patients. Depress Anxiety. 2002;16:128.

Calabrese JR et al. Citalopram treatment of fluoxet-ineintolerant depressed patients. J Clin Psychiatry.

2003;64:562.

Rush AJ et al. Bupropion-SR, sertraline or venlafaxine-XR after failure of SSRIs for depression. N EnglJ Med.

2006;354:1231.

Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the

evidence. Expert Rev Neurother. 2008;8:1787.

.

.

.

.

.

.

.

.

.

.

.

.

167.

.

.

.

.

.

.

.

.

.

.

.

.

180.

Bymaster FP et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine

transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Neuropsychopharmacology. 2001;25:871–880.

Auclair AL et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of

depression and anxiety. Neuropharmacology. 2013;70:338–347.

Deecher DC et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J

Pharmacol Exp Ther. 2006;318(2):657–665.

Nichols AI et al. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotoninnorepinephrine reuptake inhibitor. J Bioequiv Availab. 2013;5(1):22–30.

Palmer EC et al. Levomilnacipran: as serotonin-norepinephrine reuptake inhibitor for the treatment of major

depressive disorder. Ann Pharmacother. 2014:48(8):1030–1039.

Thase ME. Effect of venlafaxine on blood pressure: a meta-analysis of original data from 3744 patients. J Clin

Psychiatry. 1998;59:502–508.

Wernicke J et al. An evaluation of the cardiovascular safety profile of duloxetine. Findings from 42 placebocontrolled studies. Drug Saf. 2007;30(5):437–455.

Thase ME et al. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a

pooled analysis. Curr Med Res Opin. 2015;31(4):809–820.

Liebowitz MR et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult

outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663–1672.

Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants

vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15(17):2525–2542.

McIntyre RS et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol.

2008;4(3):281–285.

Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel

antidepressant or simply another SSRI? Expert Opin Drug Disc. 2013;8(12):1529–1539.

Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram,

levomilnacipran, sertraline, venlafaxine, and vilazodone, using nuber need to harm, and likelihood to be helped or

harmed. J Affect Disord. 2016;196:225–233.

Wang G et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive

disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–794.

Mahableshwarker AR et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and

tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology

(Berl). 2015;232:2061–2070.

Boulenger JP et al. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, doubleblind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major

depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138–149.

Boinpally R et al. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy

subjects. Clin Ther. 2014;36(11):1638–1649.

Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother. 2014;48(6):758–765.

Ascher JA et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry.

1995;56:395.

Jain AK et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res.

2002;10:1049.

Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the

literature. Pharmacotherapy. 2003;23:754.

Roose SP et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry.

1991;148:512.

De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published

correction appears in Int Clin Psychopharmacol. 1996;11:153]. Int Clin Psychopharmacol. 1995;10:19.

Wheatley DP et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate

to severe major depressive disorder. J Clin Psychiatry. 1998;59:306.

Watanabe N et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major

depression:systematic review and meta-analysis. J Clin Psychiatry. 2008;69(9):1404–1415.

Versiani M et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS

Drugs. 2005;19(2):137–146.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Guelfi JD et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic

features. J Clin Psychopharmacol. 2001;21:425.

Preston TC, Shelton RC. Treatment resistant depression: strategies for primary care. Curr Psychiatry Rep.

2013;15;370.

Ferguson JM et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double blind

comparison of nefazodone and sertraline. J Clin Psychiatry. 2001;62:24–29.

Stahl S. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536–546.

Sheehan DV et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind,

placebo-controlled study. Psychiatry. 2009;6(5):20–33.

Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet.1997;33(4):260–275.

MacGillivray S et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic

antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ.

2003;326:1014.

Katon W et al. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30:67.

Sclar D et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin

Ther. 1994;16:715.

Tran PV et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin

Psychopharmacol. 2003;23:78–86.

Rabkin JG et al. Adverse reactions to monoamine oxidase inhibitors. Part II: treatment correlates and clinical

management. J Clin Psychopharmacol. 1985;5:2.

Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med. 1984;35:503.

Cassem N. Cardiovascular effects of antidepressants. J Clin Psychiatry. 1982;43:22.

Freyschuss U et al. Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug. Pharmacologia

Clin. 1970;2:68.

Glassman AH et al. Sertraline treatment of major depression in patients with acute MI or unstable angina

[published correction appears in JAMA. 2002;288:1720]. JAMA. 2002;288:701.

Sauer WH et al. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894.

Serebrauny VL et al. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary

artery disease. Am J Cardiol. 2001;87:1398.

Bigger JT, Jr et al. Cardiac antiarrhythmic effect of 5 imipramine hydrochloride. N EnglJ Med. 1977;296:206.

Giardina EG, Bigger JT, Jr. Antiarrhythmic effect of imipramine hydrochloride inpatients with ventricular

premature complexes with psychological depression. Am J Cardiol. 1982;50:172.

Muir WW et al. Effects of tricyclic antidepressant drugs on the electrophysiological properties of dog Purkinje

fibers. J Cardiovasc Pharmacol. 1982;4:82.

Roose SP et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.

JAMA. 1998;279:287.

Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin

Pract. 2005;12:1435–1440.

Castano-Monsalve B. Antidepressants in epilepsy. Rev Neurol. 2013;57(3):117–122.

Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol. 2002;3(5):329–

339.

Zisook S. A clinical overview of monoamine oxidase inhibitors. Psychosomatics. 1985;26:240.

McGrath PJ et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical

depression. Am J Psychiatry. 2000;157:344.

Haefely W et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology

(Brel). 1992;106(Suppl):S6.

Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal

system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–

214.

Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic

review of safety and tolerability. J Affect Disord. 2008;105:15–23.

Murphy DL et al. Monoamine oxidase-inhibiting antide-pressants: a clinical update. Psychiatr Clin North Am.

1984;7:549.

Kronig MH et al. Blood pressure effects of phenelzine. J Clin Psychopharmacol. 1983;3:307.

Salzman C. Clinical guidelines for the use of antidepressant drugs in geriatric patients. J Clin Psychiatry.

.

.

.

.

.

.

.

.

.

.

.

.

225.

.

.

.

.

.

.

232.

.

.

.

.

.

.

.

.

1985;46(10, pt 2):38.

Mallinger AG et al. Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to

cardiovascular effects. Clin Pharmacol Ther. 1986;40:444.

Robinson DS et al. Clinical pharmacology of phenelzine. Arch Gen Psychiatry. 1978;35:629.

Mitchell JE, Popkin MK. Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin

Psychopharmacol. 1983;3:76.

Zhou X et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant

depression:systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487–e498.

McIntyre RS et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach.

J Affect Disord. 2014;156:1–7.

Rothschild A. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull.

2013;39(4):787–796.

Bauer M et al. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled trials

[published correction appears in J Clin Psychopharmacol. 2000;20:287]. J Clin Psychopharmacol. 1999;119:427.

Altshuler LL et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and

meta-analysis of the literature. Am J Psychiatry. 2001;158:1617.

Nierenberg AJ et al. A comparison of lithium and T3 augmentation following two failed medication treatments

for depression: a STAR-D report. Am J Psychiatry. 2006;163:1484.

Shelton RC et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24:131.

Centers for Disease Control and Prevention. Mental health surveillance among children-United States, 2005-

2011. MMWR. 2013;62(suppl 2):1–39.

Choe CJ et al. Depression. Child Adolesc Psychiatr Clin N Am. 2012;21:807–829.

Hetrick SE et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and

adolescents. Cochrane Database Syst Rev. 2007;3:art no. CD004851.

Hetrick SE et al. Newer generation antidepressants for depressive disorders in children and adolescents.

Cochrane Database Syst Rev. 2012;11:art no. CD004851.

American Academy of Child and Adolescent Psychiatry Official Action. Practice parameter for the assessment

and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry .

2007;46(11):1503–1526.

Cheung AH et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing

management. Pediatrics. 2007;120(5):e1313–e1326.

Wagner KD et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of

pediatric depression. J Amer Acad Child Adolesc Psychiatry. 2006;45(3):280–288.

Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev.

2013;6:CD002317.

Bridge JA et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric

antidepressant treatment. A meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–1696.

Schneeweiss S et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal

acts. Pediatrics. 2010;125(5):876–888.

Isacsson G, Ahlner J. Antidepressants and the risk of suicide in young persons-prescription trends and

toxicological analyses. Acta Psychiatr Scand. 2014;129:296–302.

Worsening depression and suicidality in patients being treated with antidepressants. U.S. Food and Drug

Administration Web site.

http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf. Accessed

April 24, 2016.

Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and

their combination for adolescents with depression. Treatment for adolescents with depression study (TADS)

randomized controlled trial. JAMA. 2004;292:807–820.

Shanmugham B et al. Evidence-based pharmacologic interventions for geriatric depression. Psychiatr Clin North

Am. 2005;28:821–835.

Juurlink D et al. Medical illness and the risk of suicide in the elderly. Arch Intern Med. 2004;164:1179–1184.

Reding M et al. Depression in patients referred to a dementia clinic: a three year prospective study. Arch

Neurol. 1985;42:894.

Meyers BS, Bruce ML. The depression-dementia conundrum. Arch Gen Psychiatry. 1998;55:102.

Green RC et al. Depression as a risk factor for Alzheimer disease. Arch Neurol. 2003;60:753.

.

.

.

.

.

.

247.

.

.

.

.

.

Cummings JL. Dementia and depression: an evolving enigma. J Neuropsychiatry Clin Neurosci. 1989;1:236.

Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann

Pharmacother. 2006;40:1618–1622.

Asberg M et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ. 1971;3:331.

Glassman AH et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen

Psychiatry. 1977;34:197.

Nelson JC et al. Desipramine plasma concentrations and antidepressant response. Arch Gen Psychiatry.

1982;39:1419.

Ziegler VE et al. Amitriptyline plasma levels and therapeutic response. Clin Pharmacol Ther. 1976;19:795.

Moyes IC et al. Plasma levels and clinical improvement—a comparative study of clomipramine and amitriptyline

in depression. Postgrad Med J. 1980;56(Suppl 1):127.

Robinson DS et al. Plasma tricyclic drug levels in amitriptyline-treated depressed patients. Psychopharmacology.

1979;63:223.

The use of laboratory tests in psychiatry: tricyclic antidepressants—blood level measurements and clinical

outcome. An APA Task Force Report. Am J Psychiatry. 1985;142(2):155–162.

Linder MW, Keck PE, Jr. Standards of laboratory practice: antidepressant drug monitoring. Clin Chem.

1998;44:1073.

Robinson MJ et al. Depression and pain. Front Biosci (Landmark Ed). 2009;14:5031–5051.

Rijavec N, Grubic VN. Depression and pain: often together but still a clinical challenge—a review. Psychiatr

Danub. 2012;24(4):346–352.

p. 1833

Bipolar disorder is a chronic progressive illness that occurs in

approximately 4% of the population. It is characterized by recurrent

mood episodes of mania and depression. Life stressors, substance use,

treatment non-adherence, and medications are common precipitants of

these mood episodes.

Case 87-1 (Questions 1–3)

Manic episodes are characterized by elevated mood, irritability,

increased goal-directed activity, inflated self-esteem, poor judgment, and

excessive motor activity.

Case 87-1 (Question 1),

Case 87-2 (Question 1)

Depressive episodes of bipolar share the same diagnostic criteria as

major depressive disorder, including depressed mood, decreased

interest, feelings of worthlessness, diminished ability to concentrate, and

recurrent thoughts of death.

Case 87-7 (Question 1)

Valproate, lithium, or atypical antipsychotics are appropriate first-line

treatments for acute mania. Depending on the severity of symptoms,

these agents may be used alone or in combination.

Case 87-1 (Questions 4, 5),

Case 87-2 (Question 1),

Case 87-5 (Question 2),

Case 87-6 (Question 1)

Lithium, lamotrigine, quetiapine, lurasidone, or the combination of these

agents is appropriate treatments for bipolar depression.

Case 87-7 (Question 1)

Maintenance treatment of bipolar disorder is imperative to prevent

disease progression. The standard of practive is to continue the acutephase treatment with gradualsimplification toward monotherapy, if

possible, with lithium, lamotrigine, valproate, or atypical antipsychotics.

Case 87-5 (Question 1),

Case 87-8 (Questions 1, 2)

Medications used to treat bipolar disorder have a wide range of adverse

effects that may impact adherence. The history of response, patient

preference, and long-term tolerability profile are important

considerations when selecting an agent. Therapeutic blood level

monitoring, as well as laboratory monitoring for adverse effects, is

commonly required for certain medications.

Case 87-1 (Questions 6–8),

Case 87-2 (Questions 1–8),

Case 87-3 (Questions 1, 2),

Case 87-4 (Questions 1, 2)

Non-pharmacologic treatments including electroconvulsive therapy

(ECT) and herbalsupplements are important considerations for the

treatment of bipolar disorder.

Case 87-8 (Questions 3, 4)

INTRODUCTION

Bipolar disorder (BD), once known as manic depression, is a severe life-threatening

psychiatric condition that is commonly misdiagnosed and too often insufficiently

treated.

1,2 BD is associated with high rates of healthcare utilization, suicidal

behavior, and use of public assistance.

3 The global burden of BD is immense,

exceeding many chronic diseases including human immunodeficiency virus, diabetes

mellitus, and asthma.

4

Epidemiology

Using DSM-IV-TR criteria, the 12-month prevalence of bipolar I disorder is

estimated to be 0.6%; bipolar II disorder is marginally more common at 0.8%.

5 The

prevalence rate for the bipolar spectrum of illnesses, which include bipolar I,

bipolar II, and subthreshold BD (i.e., Bipolar Disorder Not Otherwise Specified

[NOS]), is 4.4%.

6 Bipolar I and II are more common in women than in men, whereas

subthreshold illness predominates in men.

6 The familial nature of BD has been well

established with an

p. 1834

p. 1835

11-fold increased risk in first-degree relatives.

7 Twin studies add further support to

the genetic linkage. Goodwin and Jamison reported a 63% concordance rate (rate of

illness in co-twin of affected proband) for monozygotic twins compared with 13%

for dizygotic twins.

7

The estimated total U.S. economic burden of BD between 1991 and 2009 was

reported to be $151 billion.

8 Direct costs, such as hospitalization, outpatient visits,

and medications, accounted for 20% of the total. The remaining 80% was attributable

to indirect costs such as lost productivity by patients and caregivers.

The mean age of onset of symptoms for the bipolar spectrum of illnesses is 21

years.

6 Bipolar I is the earliest in onset at age 18, compared with bipolar II at age 20

and subthreshold BD occurring at age 22.

6 Approximately 20% to 30% of new cases

occur in children between 10 and 15 years old.

9,10 Late-life onset of BD is rare. After

age 60, there is a sharp reduction in the new onset of BD; therefore, a presentation of

mania at this age should alert the clinician to an underlying medical problem as the

possible cause.

11

Patients may present initially with any affective episode, but it is important to note

that 75% of patients report having had multiple episodes of depression before the

development of a manic episode.

9 Not surprisingly, misdiagnosis (primarily as major

depressive disorder) is common, occurring in roughly 70% of patients.

9 By some

accounts, one in four patients visit as many as five physicians before an accurate

diagnosis is made. A significant contribution to misdiagnosis is the underreporting of

manic symptoms, which are not considered to be particularly problematic by

patients.

9

BD is a recurrent illness; single episodes of mania, unrelated to BD, occur in

fewer than 10%.

12 Most patients with BD suffer multiple episodes of mania,

hypomania, or depression separated by periods of euthymia (stable mood) throughout

the course of their lives. In the majority, mania occurs just before or immediately

after a depressive episode.

12 There may be a 5- to 10-year period from the onset of

illness until the first hospitalization or diagnosis of BD.

11